Successful renal transplantation despite low levels of donor-specific HLA class I antibody without IVIg or plasmapheresis

Clinical Transplantation

Volumn 20, Issue 5, 2006, Pages 563-570

  Bryan, Christopher F ^a   McDonald, Scott B ^a   Luger, Alan M ^b   Shield, Charles F ^c   Winklhofer, Franz T ^d   Borkon, A Michael ^e   Warady, Bradley A ^f   Aeder, Mark I ^g   Murillo, Daniel ^h  

^a Midwest Transplant Network   (United States)

^b University Hospital   (United States)

^c Via Christi Rehabilitation Center   (United States)

^d UNIVERSITY OF KANSAS HOSPITAL   (United States)

^e ST LUKE S HOSPITAL   (United States)

^f CHILDREN S MERCY HOSPITAL   (United States)

^g CASE WESTERN RESERVE UNIVERSITY   (United States)

^h Research Medical Center Brookside Campus   (United States)

Author keywords

Antibody; Class I; Graft; HLA; Renal; Survival; Transplantation

Indexed keywords

ANTIBIOTIC AGENT; CARIMMUNE; CD20 ANTIBODY; HLA ANTIBODY; HLA ANTIGEN CLASS 1; IMMUNOGLOBULIN G; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY TITER; ARTICLE; CADAVER KIDNEY; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; FEMALE; FLOW CYTOMETRY; FOLLOW UP; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HEART SURGERY; HUMAN; HUMORAL IMMUNITY; KIDNEY GRAFT REJECTION; KIDNEY ISCHEMIA; KIDNEY TRANSPLANTATION; PANCREAS TRANSPLANTATION; PERIOPERATIVE PERIOD; PLASMAPHERESIS; PREOPERATIVE CARE; PRIORITY JOURNAL; PROPHYLAXIS; PROSPECTIVE STUDY; SPLENECTOMY; T LYMPHOCYTE; TISSUE TYPING;

BLOOD GROUP INCOMPATIBILITY; GRAFT SURVIVAL; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; ISOANTIBODIES; KIDNEY TRANSPLANTATION; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33748667512     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2006.00563.x     Document Type: Article

References (20)

1. Jordan SC, Vo A, Bunnapradist S et al. Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Transplantation 2003: 76: 631.
2. Jordan S, Cunningham-Rundles C, McEwan R. Utility of intravenous immune globulin in kidney transplantation: Efficacy, safety, and cost implications. Am J Transplant 2003: 3: 653.
3. Zachary AA, Montgomery RA, Ratner LE et al. Specific and durable elimination of antibody to donor HLA antigens in renal-transplant patients. Transplantation 2003: 76: 1519.
4. Scornik JC, Clapp W, Patton PR et al. Outcome of kidney transplants in patients known to be flow cytometry crossmatch positive. Transplantation 2001: 71: 1098.
5. O'Rourke RW, Osorio RW, Freise CE et al. Flow cytometry crossmatching as a predictor of acute rejection in sensitized recipients of cadaveric renal transplants. Clin Transplant 2000: 14: 167.
6. Kerman RH, Susskind B, Buyse I et al. Flow cytometry-detected IgG is not a contraindication to renal transplantation. Transplantation 1999: 68: 1855.
7. Karpinski M, Rush D, Jeffery J et al. Flow cytometric crossmatching in primary renal transplant recipients with a negative anti-human globulin enhanced cytotoxicity crossmatch. J Am Soc Nephrol 2001: 23: 2807.
8. Bryan CF, Baier KA, Nelson PW et al. Long-term graft survival is improved in cadaveric renal retransplantation by flow cytometric crossmatching. Transplantation 1998: 66: 1827.
9. Bryan CF, McDonald SB, Baier KA et al. Flow cytometry beads rather than the antihuman globulin method should be used to detect HLA class I IgG antibody (PRA) in cadaveric renal regraft candidates. Clin Transplant 2002: 16 (Suppl. 7): 15.
10. Pei R, Lee J, Shih N, Chen M, Terasaki PI. Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities. Transplantation 2003: 75: 43.
11. Gloor JM, Mai ML, De Goey SR. Kidney transplantation following administration of high dose IVIg in patients with positive flow cytometric/negative enhanced cytotoxicity crossmatch. Am J Transplant 2004: 4 (Suppl. 8): 256.
12. Salama AD, Delikouras A, Pusey CD et al. Transplant accommodation in highly sensitized patients: A potential role for Bcl-xL and alloantibody. Am J Transplant 2001: 1: 260.
13. Jin YP, Fishbein MC, Said JW et al. Anti-HLA class I antibody-mediated activation of the PI3K/Akt signaling pathway and induction of Bcl-2 and Bcl-xL expression in endothelial cells. Hum Immunol 2004: 65: 291.
14. Narayanan K, Jaramillo A, Phelan DL, Mohanakumar T. Pre-exposure to sub-saturating concentrations of HLA class I antibodies confers resistance to endothelial cells against antibody complement-mediated lysis by regulating Bad through the phosphatidylinositol 3-kinase/Akt pathway. Eur J Immunol 2004: 34: 1.
15. Gebel HM, Bray RA. Sensitization and sensitivity. Transplantation 2000: 69: 1370.
16. Gebel HM, Bray RA, Nickerson P. Pre-transplant assessment of donor-reactive, HLA-specific antibodies in renal transplantation: contraindication vs. risk. Am J Transplant 2003: 3: 1489.
17. Karuppan SS, Ohlman S, Moller E. The occurrence of cytotoxic and non-complement-fixing antibodies in the crossmatch serum of patients with early acute rejection episodes. Transplantation 1992: 54: 839.
18. Fuller TC, Fuller A. The humoral immune response against an HLA class I allodeterminant correlates with the HLA-DR phenotype of the responder. Transplantation 1999: 68: 173.
19. Dankers MKA, Roelen DL, Nagelkerke NJD et al. The HLA-DR phenotype of the responder is predictive of humoral response against HLA class I antigens. Hum Immunol 2004: 65: 13.
20. Heise E, Manning C, Thacker L. HLA phenotypes of ESRD patients are risk factors in the panel-reactive antibody (PRA) response. Clin Transplant 2001: 15 (Suppl. 6): 22.